Latham Advises on Orchestra BioMed’s US$40 Million Public Offering

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, Orchestra BioMed or the Company), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced the pricing of an underwritten public offering of 9,413,637 shares of its common stock at a price to the public of US$2.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 5,136,363 shares of its common stock at a price to the public of US$2.7499 per pre-funded warrant, which represents the per share public offering price for the shares of common stock less the US$0.0001 per share exercise price for each pre-funded warrant (the Offering). In addition, the Company granted the underwriters a 30-day option to purchase up to an additional 2,182,500 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the securities are being offered by the Company. The Offering is expected to close on August 4, 2025, subject to customary closing conditions.

Latham & Watkins LLP is advising the underwriters in the offering, with a capital markets team led by New York partner Nathan Ajiashvili, with associates Matt DeSilva, Zoey Wu, Yulong Li, and Connor Jobes.